News

Third Rock's faded Ember gets resuscitated in merger deal

Ember Therapeutics, a Third Rock Ventures-founded biotech startup that closed its doors late last year, is getting a second chance thanks to a small New York drug developer.

Allergy biotech hauls in $80M for its oral immunotherapy

Food allergy upstart Allergen Research Corporation raised an $80 million B round to get its lead candidate into late-stage development, pushing ahead with a treatment for peanut allergies.

Sanofi backs immunotherapy hub, U.K. mulls its own 'breakthrough,' Allergy player banks £20M

In this week's EuroBiotech Report, Marseille made a pitch to turn its rich history of immunity research into a seat at the top table of immunotherapy R&D. Sanofi and Innate Pharma have signed up as founders of the lab at the center of the push, which hopes to turn scientific hypotheses into preclinically validated, licensing-ready research programs. And more.

Sustainable bull market or biotech bubble? What do you think?

Well over 300 responses have been gathered so far, which is not a bad beginning for our first survey.

U.K. looks to FDA 'breakthrough' status for inspiration in regulatory revamp

The United Kingdom government has established the scope of the hotly anticipated review into the development and reimbursement of drugs. And the independent panel is being tasked with looking beyond the U.K.'s borders for inspiration, with an analysis of what can be learnt from the U.S. FDA's "breakthrough" designation on its to-do list.

Neuralstem tanks on cloudy results for its ALS treatment

Neuralstem unveiled positive top-line safety results for its in-development ALS therapy, but some murky efficacy data led investors to question the future of the stem cell treatment, sending the biotech's shares down as much as 25%.

Epizyme retrieves global rights to cancer drug in $110M deal

Pumped by the potential commercial impact of their EZH2 inhibitor EPZ-6438, Epizyme is dragging back global rights to the drug in what the Cambridge, MA-based biotech is calling a "transformative" deal.

23andMe dives into biotech with Genentech R&D star Richard Scheller on board

Since its foundation in 2006, 23andMe has gathered genetic info on more than 850,000 people by processing spit tests at $99 a pop. Now the Mountain View, CA, outfit is planning to mine that trove of data for drug targets, transforming into a biotech company and hiring a decorated ex-Genentech luminary to steer the way.

J&J partner Aduro rides the immuno-oncology wave with $86M IPO

Aduro Biotech is taking its "breakthrough" set of immuno-oncology projects to Wall Street, where they will see if investors still have a big appetite for biotech IPOs. The company filed its S-1 on Wednesday, laying out its case for an $86 million initial offering that will help fund its late-stage work in the field.

AstraZeneca gambles on a $40M round for diabetes/cardio biotech PhaseBio

Malvern, PA-based PhaseBio rounded up $40 million in Series C money to pursue its R&D dreams in the diabetes arena, bringing in pharma giant AstraZeneca as a backer in the process.

Kura sheds stealth mode with $60M for PhII cancer drug licensed from J&J

Four years after executing a $310 million deal to sell Intellikine to Takeda, biotech entrepreneur Troy Wilson is back, springing out of stealth mode with a new company that has a full team, $60 million in financing, a cancer drug in-licensed from Johnson & Johnson and a plan to start mid-stage development with two Phase II studies launching later in the year. And he's done it while working out an OTC listing that puts him in a public market with an eye to moving up to one of the national exchanges.

Alcobra misses efficacy endpoint in ADHD trial

Alcobra's attention deficit hyperactivity disorder (ADHD) drug MDX has failed to statistically outperform the placebo in a Phase II trial. The outcome meant the trial missed its secondary efficacy endpoint, but Alcobra did its best to talk up the significance of the positive safety data.

Allergy Therapeutics raises £20M to bounce back from 5-year clinical hold

Allergy Therapeutics has turned to public investors for £20 million ($30 million) to move its subcutaneous immunotherapy allergy vaccine through late-phase development. The cash will fund Allergy Therapeutics' attempt to bounce back from the 5-year clinical hold of its U.S. trial program.

Acadia craters as takeover buzz is silenced by (another) NDA delay, CEO exit

San Diego-based Acadia Pharmaceuticals put out word on Wednesday evening that it is delaying its expected NDA for pimavanserin from Q1 back to some time in the second half of this year. And the company says its CEO is out the door.

Glaxo plants a flag in Singapore with CEO Witty on hand

GlaxoSmithKline planted its flag in Singapore to build on a close relationship with the government of the wealthy city-state where CEO Andrew Witty worked and lived earlier in his career with the U.K. drugmaker.

AgeneBio scouts deals and dollars ahead of Alzheimer's PhIII

AgeneBio, founded by Johns Hopkins investigator Michela Gallagher, says the numbers in a midstage study back up its case that its drug works against Alzheimer's--a story that the company hopes will deliver the support needed to pursue a Phase III study.

Intrexon partner AmpliPhi raises $13M for antibiotic R&D

AmpliPhi BioSciences has lined up $13 million in private placement cash, selling stock and warrants to fund its pipeline of treatments for drug-resistant bacterial infections.

The Fierce survey: Is this a biotech bubble or a sustainable bull market?

We here at Fierce are turning to the industry to get your opinion. Please register your vote on a sustainable bull market in biotech vs. a bubble. And we'd like to hear your thoughts on the subject. Final results will be revealed on Monday

Acadia's shifting calendar spurs market-moving takeout rumors

Acadia Pharmaceuticals' shares rocketed up nearly 20% on Tuesday based on some news tied to two investor conferences. But the market wasn't reacting to anything the company said, instead reading into a pair of cancellations and deducing that a buyout might be in the offing.

Sanofi backs pitch to turn Marseille into an immunotherapy R&D hub

The French city of Marseille has staked its claim for a corner of the booming immunotherapy R&D ecosystem. And the plan has some big-name backers, with Sanofi and Innate Pharma both signing up as founders of the MI-mAbs immunotherapy research center in the city.